Tobin Schilke
Director of Finance/CFO bei REVANCE THERAPEUTICS, INC.
Vermögen: 947 917 $ am 31.03.2024
Profil
Tobin C.
Schilke is currently the Chief Financial Officer at Revance Therapeutics, Inc. He previously held the position of Chief Financial Officer & Executive Director at Roche Products Ltd.
from 2012 to 2016.
Prior to that, he was the Director-Commercial Financial Planning & Analysis at Genentech, Inc. from 2012 to 2014.
From 2016 to 2018, he served as the Chief Financial Officer at Achaogen, Inc. Mr. Schilke completed his undergraduate degree at Lafayette College and his graduate degree at the University of California, Berkeley.
He also holds an MBA from the Johnson Graduate School of Management.
Bekannte Unternehmensbeteiligungen
Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
---|---|---|---|---|
18.03.2024 | 192 666 ( 0,18% ) | 947 917 $ | 31.03.2024 |
Aktive Positionen von Tobin Schilke
Unternehmen | Position | Beginn |
---|---|---|
REVANCE THERAPEUTICS, INC. | Director of Finance/CFO | 05.11.2018 |
Ehemalige bekannte Positionen von Tobin Schilke
Unternehmen | Position | Ende |
---|---|---|
ACHAOGEN | Director of Finance/CFO | 01.10.2018 |
Roche Products Ltd.
Roche Products Ltd. Pharmaceuticals: MajorHealth Technology Roche Products Ltd. manufactures diagnostic, diabetes, and pharmaceutical products. The company was founded on December 14, 1908 and is headquartered in Welwyn Garden City, the United Kingdom. | Director of Finance/CFO | 01.06.2016 |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Corporate Officer/Principal | 01.08.2014 |
Ausbildung von Tobin Schilke
Lafayette College | Undergraduate Degree |
University of California, Berkeley | Graduate Degree |
Johnson Graduate School of Management | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
REVANCE THERAPEUTICS, INC. | Health Technology |
Private Unternehmen | 3 |
---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
Achaogen, Inc.
Achaogen, Inc. Pharmaceuticals: MajorHealth Technology Achaogen, Inc. engages in developing and commercializing innovative antibacterial agents for multi-drug resistant gram-negative infections. The firm is also involved in the development of C-Scape, an orally administered antibiotic to address a serious unmet need for an effective oral treatment for patients with complicated urinary tract infections, including pyelonephritis caused by extended spectrum beta-lactamases producing Enterobacteriaceae. The company was founded by Nathaniel Eames David, Floyd E. Romesberg, and Peter G. Schultz in June 2002 and is headquartered in South San Francisco, CA. | Health Technology |
Roche Products Ltd.
Roche Products Ltd. Pharmaceuticals: MajorHealth Technology Roche Products Ltd. manufactures diagnostic, diabetes, and pharmaceutical products. The company was founded on December 14, 1908 and is headquartered in Welwyn Garden City, the United Kingdom. | Health Technology |